DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Lipid-based nanovesicles for nanomedicine
Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as
lipid-based nanovesicles (L-NVs). The oldest L-NVs, liposomes, have been widely proposed as potential
candidates for drug delivery, diagnostic and/or theranostic applications and some liposome-based drug
products have already stepped from the lab-bench to the market. This success is attributed to their
ability to encapsulate both hydrophobic and/or hydrophilic molecules, efficiently carry and protect them
within the body and finally deliver them at the target site. These positive features are also coupled with
high biocompatibility. However, liposomes still present some unsolved drawbacks, such as poor colloidal
stability, short shelf-life, restricted and expensive conditions of preparation because of the inherent
nature of their fundamental constituents (phospholipids). The new tools available in the self-assembly of
controlled molecules have significantly advanced the field of L-NV design and synthesis, and nonliposomal
L-NVs have been recently developed; this new generation of nanovesicles can represent a
paradigm shift in nanomedicine: they may complement liposomes, showing their advantages and
overcoming most of their drawbacks. Clearly, being still young, their rocky way to the clinic first and
then to the market has just started and it is still long, but they have all the potentialities to reach their
objective target. The purpose of this review is to first present the large plethora of L-NVs available,
focusing on this new generation of non-liposomal L-NVs and showing their similarities and differences
with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is
also strongly dependent on the availability of technological-scale preparation methods, we will also
extensively review the current approaches exploited for L-NV production. The most cutting-edge
approaches based on compressed fluid (CF) technologies will be highlighted here since they show the
potential to represent a game-change in the production of L-NVs, favouring their step from the bench
to the market. Finally, we will briefly discuss L-NV applications in nanomedicine, looking also for their
future perspectives., This work was financially supported by MINECO (DGI), Spain, grants BE-WELL CTQ2013-40480-R, TERARMET (RTC-2014-2207-1), QUATFORFRAG (RTC-2014-2183-5) and UNDERLIPIDS (RTC-2015-3303-1), and by AGAUR, Generalitat de Catalunya, “Grant 2014-SGR-17“. N.G. acknowledges the European Commission (EC) (FP7-PEOPLE-2013-Initial Training Networks (ITN) ‘‘NANO2FUN’’ Project No. 607721) for their Postdoctoral contract. The authors appreciate support from LIPOCELL project financed by CIBER-BBN and Praxis Pharmaceuticals and also acknowledge the financial support from Instituto de Salud Carlos III, through “Acciones CIBER”. The Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) is an initiative funded by the VI National R&D&I Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 CTQ2013-40480-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RTC2014-2207-1-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RTC2014-2183-5-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RTC2015-3303-1-R